Hostname: page-component-586b7cd67f-gb8f7 Total loading time: 0 Render date: 2024-11-30T23:53:29.403Z Has data issue: false hasContentIssue false

Inducible Beta Lactamases in Enterobacteriaceae and Pseudomonas: Problems for the New Beta Lactam Antibiotics

Published online by Cambridge University Press:  02 January 2015

Christine C. Sanders*
Affiliation:
Department of Medical Microbiology, Creighton University School of Medicine, Omaha, Nebraska

Abstract

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Departments
Copyright
Copyright © The Society for Healthcare Epidemiology of America 1982

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Reference

1. Sanders, CC. Sanders, WE Jr: Emergence of resistance to cefamandole: Possible role of cefoxitin-inducible beta lactamases. Antimicrob Agents Chemother 15:792797, 1979.Google Scholar

Bibliography

Sanders, CC, Mollering, RC Jr, Martin, RR, et al: Resistance to cefaman-dole: A collaborative study of emerging clinical problems. J Infect Dis 145:118125, 1982.Google Scholar
Beckwith, DG, Jahre, JA: Role of a cefoxitin inducible beta lactamase in a case of breakthrough bacteremia. J Clin Microbiol 12:517520. 1980.Google Scholar
Gootz, TD, Sanders, CC, Goenng, RV: Resistance to cefamandole: depression of β-lactamases by cefoxitin and mutation in Enterobacter cloacae . J Infect Dis July 1982 (in press).Google Scholar
Sanders, CC, Sanders, WE Jr, Goering, RV: In vitro antagonism of beta lactam antibiotics by cefoxitin. Antimicrob Agents Chemother June 1982 (in press).Google Scholar
Simon, GL, Snydman, DR, Tally, KP, et al: Clinical trial of piperacillin with acquisition of resistance by Pseudomonas and clinic al relapse. Antimicrob Agents Chemother 18:167170, 1980.Google Scholar
Winston, DJ, Busuttil, RW, Kurtz, TO, et al: Moxalactam therapy for bacterial infections. Arch Intern Med 141:16071612, 1981.Google Scholar
Karakusis, PH, Feczko, JM, Goodman, LJ, et al: Clinical efficacy of cefotaxime in serious infections. Antimicrob Agents Chemother 21:119124, 1982.Google Scholar